Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 4673 (miR-4673)
- Target
- miR-4673
- Molecular classification
- MicroRNA (miRNA), Non-coding RNA, Other
01
Overview
MicroRNA 4673 is a regulatory non-coding RNA molecule encoded within the Notch-1 gene in humans. It instructs bimodal reprogramming of the cell cycle in neural progenitors by synchronizing cells at the G0 phase and then accelerating progression through interphase. This is achieved by transient inhibition of cyclin-dependent kinase 18 (CDK18), promoting autophagic degradation of p53/p21, transcriptional silencing of XRCC3/BRCA2, and modulation of signaling pathways such as Wnt/Catenin-β1. The net effect is a substantial amplification of proliferative capacity, delay in differentiation, and a bias in neural fate toward inhibitory interneurons. This unique activity—combining cell cycle synchronization, accelerated progression, and ontogenetic patterning—suggests miR-4673 plays a critical role in neurogenesis and could inform future strategies for regenerative or oncologic therapies, though it is not yet a classic drug target[1][2].
- Other names
- hsa-mir-4673microRNA4673MIR4673
02
Mechanism of action
Not applicable; no current drugs target miR-4673.
03
Biological functions
Regulation of cell cycle, specifically bimodal reprogramming leading to initial synchronization of neural progenitors at G0, followed by accelerated progression through interphaseSuppression of differentiation propensity in neural stem/progenitor cells, promoting proliferation and delaying differentiationAutophagy induction and modulation of cell cycle checkpoints (downregulation of p53/p21, transcriptional silencing of XRCC3/BRCA2)Neurogenesis modulation, including sublineage fate bias toward GABAergic interneurons
04
Disease associations
Central nervous system development/disease: Impacts the proliferative capacity and fate determination of neural progenitorsPotential implications in cancer, as modulation of cell cycle, proliferation, and differentiation is a typical oncogenic pathway (inference from related miRNA roles[2])
05
Safety considerations
Not established for direct targeting of miR-4673. Therapeutic modulation of miR-4673 could carry risks typical of microRNA therapies, such as off-target effects and disruption of critical gene networks controlling proliferation and differentiation[2]
06
Biomarkers
miR-4673 levels could be explored as biomarkers for cell cycle status, neural stem/progenitor proliferation, or neurodevelopmental outcomes (based on its function[1]; not currently established in clinical use)
Beyond the preview
Go deeper on MicroRNA 4673 (miR-4673).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MicroRNA 4673 (miR-4673).